Clinical Trial Update: Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC [Phase 1, Phase 2]

View source ↗

Summary

Early-phase trial investigating sintilimab plus a bevacizumab biosimilar for potentially resectable intermediate hepatocellular carcinoma (PHASE 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab biosimilar (Bevacizumab)
• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN